Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ABT-263 Clear all
Withdrawn Phase 2 Interventional

A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)

NCT01423539
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
bendamustine, navitoclax, rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Fountain Valley, California • Hudson, Florida • Lawrenceville, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 17, 2026, 2:08 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL

NCT05215405
View directory record Official record
Conditions
Relapsed Childhood ALL, Relapsed Childhood Lymphoblastic Lymphoma
Interventions
Venetoclax, Navitoclax
Drug
Lead sponsor
Kathleen Ludwig
Other
Eligibility
4 Years and older
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 2 Interventional

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

NCT01087151
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
ABT-263, rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
48
States / cities
Alhambra, California • Antioch, California • Berkeley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

NCT00878449
View directory record Official record
Conditions
Solid Tumors
Interventions
ABT-263, etoposide/cisplatin
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Chicago, Illinois • Maywood, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

NCT00788684
View directory record Official record
Conditions
CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma
Interventions
rituximab, ABT-263
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
4
States / cities
Tucson, Arizona • Stanford, California • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 17, 2026, 2:08 PM EDT
Active, not recruiting Phase 1 Interventional

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

NCT05222984
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Decitabine, Navitoclax, Venetoclax
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
16 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

NCT04472598
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
Placebo for Navitoclax, Ruxolitinib, Navitoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
35
States / cities
Springdale, Arkansas • Fullerton, California • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

NCT02520778
View directory record Official record
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Navitoclax, Osimertinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
18
States / cities
Sacramento, California • Aurora, Colorado • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer

NCT00888108
View directory record Official record
Conditions
Solid Tumor
Interventions
ABT-263, Docetaxel
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Fort Lauderdale, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

NCT01021358
View directory record Official record
Conditions
Lymphoma, Chronic Lymphocytic Leukemia, Solid Tumors
Interventions
ABT-263, Ketoconazole
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2010 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

NCT00406809
View directory record Official record
Conditions
Chronic Lymphoid Leukemia, Lymphoid Malignancies, Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Peripheral T-cell Lymphoma
Interventions
ABT-263
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 99 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Bethesda, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Oral Bioavailability of a New ABT-263 Formulation in Healthy Female Subjects

NCT01053520
View directory record Official record
Conditions
Healthy Female Subjects
Interventions
ABT-263
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2010 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Assess the Oral Bioavailability of New ABT-263 Formulations

NCT00743028
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Lymphomas, Leukemias
Interventions
ABT-263
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
5
States / cities
Encinitas, California • Santa Monica, California • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2010 · Synced Oct 17, 2026, 2:08 PM EDT
Active, not recruiting Phase 1 Interventional

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

NCT05455294
View directory record Official record
Conditions
Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia, Myeloproliferative Neoplasm
Interventions
Navitoclax, Venetoclax, Decitabine
Drug
Lead sponsor
Jacqueline Garcia, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

NCT03222609
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
Ruxolitinib, Navitoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
33
States / cities
Birmingham, Alabama • Cerritos, California • Duarte, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 17, 2026, 2:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

NCT01989585
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm, Metastatic Melanoma, Unresectable Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Dabrafenib, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Navitoclax, Pharmacological Study, Trametinib
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
49
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 17, 2026, 2:08 PM EDT
Active, not recruiting Phase 1 Interventional

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

NCT04454658
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
ABBV-744, Navitoclax, Ruxolitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Sacramento, California • Lebanon, New Hampshire • Buffalo, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

NCT03181126
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma
Interventions
Navitoclax, Chemotherapy, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
4 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
12
States / cities
Duarte, California • Palo Alto, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 17, 2026, 2:08 PM EDT
Active, not recruiting Phase 1 Interventional

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

NCT04041050
View directory record Official record
Conditions
Myeloproliferative Neoplasm
Interventions
Navitoclax, Ruxolitinib, Celecoxib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
12
States / cities
Duarte, California • Fullerton, California • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

NCT05564650
View directory record Official record
Conditions
Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome
Interventions
Navitoclax, Venetoclax, Decitabine, Bone Marrow Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Biological · Drug · Procedure + 1 more
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

NCT02143401
View directory record Official record
Conditions
Cirrhosis, Hepatitis B Infection, Hepatitis C Infection, Metastatic Malignant Solid Neoplasm, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Malignant Neoplasm, Stage IV Hepatocellular Carcinoma AJCC v7, Unresectable Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Navitoclax, Pharmacological Study, Sorafenib, Sorafenib Tosylate
Other · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
10
States / cities
Scottsdale, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 17, 2026, 2:08 PM EDT
Terminated Phase 1 Interventional

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

NCT04480086
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
Mivebresib, Navitoclax, Ruxolitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Stony Brook, New York • Cincinnati, Ohio • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT00481091
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
ABT-263
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
6
States / cities
La Jolla, California • Boston, Massachusetts • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 17, 2026, 2:08 PM EDT
Completed Phase 2 Interventional

Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)

NCT01557777
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Navitoclax
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Pleasant Hill, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Oct 17, 2026, 2:08 PM EDT